PMID- 32329187
OWN - NLM
STAT- MEDLINE
DCOM- 20210929
LR  - 20220531
IS  - 2042-6984 (Electronic)
IS  - 2042-6976 (Linking)
VI  - 10
IP  - 11
DP  - 2020 Nov
TI  - Specific sublingual immunotherapy in children with perennial rhinitis: a systemic 
      review and meta-analysis.
PG  - 1226-1235
LID - 10.1002/alr.22589 [doi]
AB  - BACKGROUND: Allergic rhinitis (AR) is a major public health problem and is 
      increasing worldwide. AR affects children's learning efficiency, sleep quality, 
      and other major aspects of life. Sublingual immunotherapy (SLIT) is effective and 
      safe for children with seasonal AR, but for children with perennial allergic 
      rhinitis (PAR) caused by house dust mites (HDM), its effectiveness and safety is 
      less convincing. METHODS: Medical literature databases up to 2019 were searched 
      for published and unpublished pieces of evidence. Studies were individually 
      screened by 2 reviewers against the eligibility criteria. Primary outcomes were 
      total nasal symptoms scores (TNSS) and total medication scores (TMS). The 
      secondary outcomes were total ocular symptoms scores and adverse events (AEs). 
      Random effect models and fixed-effect models were used to calculate the standard 
      mean difference (SMD) and risk ratio (RR), respectively. RESULTS: We identified 
      3772 abstracts, of which only 16 studies met our established criteria. SLIT 
      significantly reduced TNSS (SMD -1.73; 95% CI, -2.62 to -0.84; p = 0.0001) and 
      TMS (SMD -1.21; 95% CI, -1.75 to -0.67; p < 0.00001). Compared with children 
      taking placebo, children taking SLIT were 1.08 (95% CI, 1 to 1.17; p = 0.05), 
      1.15 (95% CI, 0.87 to 1.51; p = 0.32), and 1.68 (95% CI, 0.68 to 4.11; p = 0.26) 
      times more likely to develop mild, moderate, and severe AEs, respectively. 
      CONCLUSION: HDM SLIT can effectively alleviate TNSS and TMS in children with PAR, 
      but care should be taken to avoid harm due to possible adverse drug reactions.
CI  - (c) 2020 ARS-AAOA, LLC.
FAU - Chen, Liang
AU  - Chen L
AD  - Department of Pulmonary, Allergy & Clinical Care Medicine, Xiamen Chang Gung 
      Memorial Hospital, Xiamen, China.
FAU - Lei, Lijuan
AU  - Lei L
AD  - Department of Pulmonary, Allergy & Clinical Care Medicine, Xiamen Chang Gung 
      Memorial Hospital, Xiamen, China.
FAU - Cai, Yinghuang
AU  - Cai Y
AD  - Department of Pulmonary, Allergy & Clinical Care Medicine, Xiamen Chang Gung 
      Memorial Hospital, Xiamen, China.
FAU - Li, Tianlin
AU  - Li T
AD  - Department of Pulmonary, Allergy & Clinical Care Medicine, Xiamen Chang Gung 
      Memorial Hospital, Xiamen, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20200625
PL  - United States
TA  - Int Forum Allergy Rhinol
JT  - International forum of allergy & rhinology
JID - 101550261
RN  - 0 (Allergens)
RN  - 0 (Antigens, Dermatophagoides)
SB  - IM
MH  - Allergens
MH  - Animals
MH  - Antigens, Dermatophagoides
MH  - Child
MH  - Humans
MH  - Pyroglyphidae
MH  - *Rhinitis
MH  - *Rhinitis, Allergic/therapy
MH  - *Rhinitis, Allergic, Perennial
MH  - *Rhinitis, Allergic, Seasonal
MH  - *Sublingual Immunotherapy
MH  - Treatment Outcome
OTO - NOTNLM
OT  - allergic perennial rhinitis
OT  - allergic rhinitis
OT  - house dust mite
OT  - pediatric perennial rhinitis
OT  - sublingual immunotherapy
EDAT- 2020/04/25 06:00
MHDA- 2021/09/30 06:00
CRDT- 2020/04/25 06:00
PHST- 2019/12/02 00:00 [received]
PHST- 2020/04/12 00:00 [revised]
PHST- 2020/04/13 00:00 [accepted]
PHST- 2020/04/25 06:00 [pubmed]
PHST- 2021/09/30 06:00 [medline]
PHST- 2020/04/25 06:00 [entrez]
AID - 10.1002/alr.22589 [doi]
PST - ppublish
SO  - Int Forum Allergy Rhinol. 2020 Nov;10(11):1226-1235. doi: 10.1002/alr.22589. Epub 
      2020 Jun 25.